Patients with ESRD have a markedly elevated baseline risk of heart failure hospitalization and mortality independent of glucose-lowering therapy, and the observed event rates likely reflect the substantial comorbidity burden inherent to this high-risk population
[30] Severe or worsening abdominal pain , particularly if localized to the upper abdomen and radiating to the back, may indicate pancreatitisa rare but serious adverse effect included in the Warnings and Precautions section of GLP-1 medication labels
More than 75% of patients experience at least one side effect, with nausea, constipation, diarrhea, and vomiting being the most frequently reported ^2
Light speeds up the breaking down of peptide bonds, which is why amber glass bottles or opaque packages are used all along the supply chain
perhaps wariness about adding another long-term medication